Real-world study of first-line therapy with aumolertinib for elderly patients with non‑small cell lung cancer harboring EGFR mutation

Abstract

Abstract Background: Elderly patients account for approximately 70% of all NSCLC patients in China. They do not always benefit from standard treatments due to impaired organ function and multiple diseases. Our study aims to observe the efficacy and safety of aumolertinib as first-line therapy in NSCLC patients aged ≥ 65 and < 65 years in clinical practice. Patients and methods: This study enrolled patients with stage IIA-IVB EGFR-mutant NSCLC who received aumolertinib alone as first-line therapy. The efficacy and safety were compared between patients ≥ 65 and < 65 years in different subgroups using the chi-square test. The primary endpoint was objective response rate (ORR). The secondary endpoints included progression-free survival (PFS), overall survival (OS), disease control rate (DCR) and safety. Results: A total of 86 patients were included. Overall, ORR and DCR were 74.4% and 97.7%, respectively. ORR was 69.6% and 80.0% for patients ≥ 65 and < 65 years, respectively (p=0.27), and DCR was 97.8% and 97.5%, respectively (p=0.93). The median PFS (mPFS) of all patients was 24.2 months. The mPFS was 20.3 months and not reached in the ≥ 65 and < 65 years groups, respectively (p=0.18). Median OS was not reached. All AEs were not statistically different between the ≥ 65 and < 65 years groups. Conclusions: The first-line therapy with aumolertinib showed excellent and encouraging results in this real-world study. The efficacy and safety profile of aumolertinib as first-line therapy in elderly EGFR-mutant NSCLC patients were similar to that seen in the younger subgroup.